001006427 001__ 1006427
001006427 005__ 20231027114400.0
001006427 0247_ $$2doi$$a10.3390/molecules28072890
001006427 0247_ $$2Handle$$a2128/34582
001006427 0247_ $$2pmid$$a37049661
001006427 0247_ $$2WOS$$aWOS:001001567200001
001006427 037__ $$aFZJ-2023-01662
001006427 082__ $$a540
001006427 1001_ $$0P:(DE-Juel1)175142$$aNeumaier, Felix$$b0
001006427 245__ $$aMutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
001006427 260__ $$aBasel$$bMDPI$$c2023
001006427 3367_ $$2DRIVER$$aarticle
001006427 3367_ $$2DataCite$$aOutput Types/Journal article
001006427 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687840183_8046
001006427 3367_ $$2BibTeX$$aARTICLE
001006427 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001006427 3367_ $$00$$2EndNote$$aJournal Article
001006427 500__ $$aThis work was supported by Deutsche Forschungsgemeinschaft (DFG), grant number NE 890/9-1.
001006427 520__ $$aGliomas are the most common primary brain tumors in adults. A diffuse infiltrativegrowth pattern and high resistance to therapy make them largely incurable, but there are significantdifferences in the prognosis of patients with different subtypes of glioma. Mutations in isocitratedehydrogenase (IDH) have been recognized as an important biomarker for glioma classification anda potential therapeutic target. However, current clinical methods for detecting mutated IDH (mIDH)require invasive tissue sampling and cannot be used for follow-up examinations or longitudinalstudies. PET imaging could be a promising approach for non-invasive assessment of the IDH statusin gliomas, owing to the availability of various mIDH-selective inhibitors as potential leads for thedevelopment of PET tracers. In the present review, we summarize the rationale for the developmentof mIDH-selective PET probes, describe their potential applications beyond the assessment of theIDH status and highlight potential challenges that may complicate tracer development. In addition,we compile the major chemical classes of mIDH-selective inhibitors that have been described to dateand briefly consider possible strategies for radiolabeling of the most promising candidates. Whereavailable, we also summarize previous studies with radiolabeled analogs of mIDH inhibitors andassess their suitability for PET imaging in gliomas.
001006427 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001006427 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001006427 7001_ $$0P:(DE-Juel1)176188$$aZlatopolskiy, Boris D.$$b1
001006427 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b2$$eCorresponding author
001006427 773__ $$0PERI:(DE-600)2008644-1$$a10.3390/molecules28072890$$gVol. 28, no. 7, p. 2890 -$$n7$$p2890$$tMolecules$$v28$$x1420-3049$$y2023
001006427 8564_ $$uhttps://juser.fz-juelich.de/record/1006427/files/molecules-28-02890-1.pdf$$yOpenAccess
001006427 8767_ $$d2023-04-03$$eAPC$$jZahlung erfolgt
001006427 909CO $$ooai:juser.fz-juelich.de:1006427$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
001006427 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)175142$$aForschungszentrum Jülich$$b0$$kFZJ
001006427 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b2$$kFZJ
001006427 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001006427 9141_ $$y2023
001006427 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001006427 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
001006427 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-23
001006427 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001006427 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-23
001006427 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-23
001006427 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001006427 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-23
001006427 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:01:17Z
001006427 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:01:17Z
001006427 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:01:17Z
001006427 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOLECULES : 2022$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-10-22
001006427 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
001006427 920__ $$lyes
001006427 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
001006427 980__ $$ajournal
001006427 980__ $$aVDB
001006427 980__ $$aUNRESTRICTED
001006427 980__ $$aI:(DE-Juel1)INM-5-20090406
001006427 980__ $$aAPC
001006427 9801_ $$aAPC
001006427 9801_ $$aFullTexts